2m 2m 2m 2m 2m 2m 2m
- $4.8MMarket Cap
- -42.13%1-Year Change
- Packaging & ContainersIndustry
DSS (DSS)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 21
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
DSS, Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing
DSS, Inc. announced that its 2025 annual report (10-K) filed on March 31, 2026, includes a 'going concern' qualification from auditor HTL International LLC. The company clarified this announcement does not represent any change or amendment to its financial statements. DSS operates across product packaging, biotechnology, commercial lending, and securities management.
05/08/2026, 5:00 PM • GlobeNewswire
Impact Biomedical (IBO) Stock Jumps Over 86% After Hours — Here's Why
Impact Biomedical (IBO) shares surged 86.28% in after-hours trading to $0.77 following an SEC filing that disclosed amendments to its pending merger with Dr Ashleys Bio Labs Limited. The merger agreement was extended from March 31 to July 1, 2026, with revised share allocations. Dr Ashleys will issue 169.5 million shares (94.20% of total), while parent company DSS will receive 53,000 shares with potential for 75,000 additional shares if funding obligations are met.
03/04/2026, 11:38 PM • Benzinga
DSS, Inc. Announces Launch of Proposed Public Offering
DSS, Inc. (NYSE: DSS) announced the commencement of a public offering of Common Stock to raise capital for general corporate and working capital needs. Aegis Capital Corp. is serving as the sole book-running manager for the offering, which is subject to market conditions and SEC registration requirements.
02/03/2026, 8:17 PM • GlobeNewswire
DSS, Inc.'s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger
DSS, Inc. announced that its subsidiary, Impact BioMedical Inc., has entered into a definitive merger agreement with Dr. Ashleys Limited, a global pharmaceutical company. The transaction will result in a newly formed combined entity traded on the NYSE American under the name 'Dr Ashleys Limited'.
06/24/2025, 8:30 AM • Benzinga
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
DSS, Inc. operates in the product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing businesses in the United States. The company manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products. It invests in or acquires companies in the biohealth and biomedical fields, including businesses that focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases; and develops open-air defense initiatives for air-borne infectious diseases comprising tuberculosis and influenza. In addition, the company focuses on acquiring equity positions in undervalued commercial banks, bank holding companies, and nonbanking licensed financial companies; and companies engages in nonbanking activities related to banking, such as loan syndication, mortgage banking, trust and escrow, banking technology, loan servicing, equipment leasing, problem asset management, special purpose acquisition company consulting, and advisory capital raising services. Further, the company provides securities and investment management services; and operates a real estate investment trust for acquiring hospitals and other acute or post-acute care centers. Additionally, it develops and acquires assets and investments in the securities trading and funds management arena, as well as lists and operates as a digital asset on secondary market. The company was formerly known as Document Security Systems, Inc. and changed its name to DSS, Inc. in September 2021. DSS, Inc. was incorporated in 1984 and is headquartered in West Henrietta, New York.
Key Executives
- Jason T. Grady
- Todd D. Macko
- Tung Moe Chan BApSc
- Kristen Rusho
- Heng Fai Chan
Current Ownership Distribution
- Insiders545.3M (88.05%)
- Institutions37.1M (6.00%)
- Mutual Funds36.8M (5.95%)
- Other0 (0.00%)